| Adaptive designs in clinical trials: why use them, and how to run and report them P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ... BMC medicine 16, 1-15, 2018 | 681 | 2018 |
| Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial AL Ahern, GM Wheeler, P Aveyard, EJ Boyland, JCG Halford, AP Mander, ... The Lancet 389 (10085), 2214-2225, 2017 | 237 | 2017 |
| How to design a dose-finding study using the continual reassessment method GM Wheeler, AP Mander, A Bedding, K Brock, V Cornelius, AP Grieve, ... BMC medical research methodology 19, 1-15, 2019 | 99 | 2019 |
| Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia C Roddie, J Dias, MA O'Reilly, M Abbasian, A Cadinanos-Garai, ... Journal of Clinical Oncology 39 (30), 3352-3363, 2021 | 96 | 2021 |
| Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs T Burnett, P Mozgunov, P Pallmann, SS Villar, GM Wheeler, T Jaki BMC medicine 18, 1-21, 2020 | 83 | 2020 |
| Adaptive designs for dual-agent phase I dose-escalation studies JA Harrington, GM Wheeler, MJ Sweeting, AP Mander, DI Jodrell Nature Reviews Clinical Oncology 10 (5), 277-288, 2013 | 76 | 2013 |
| Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial A Jayaram, A Wingate, D Wetterskog, G Wheeler, CN Sternberg, R Jones, ... Annals of Oncology 32 (6), 726-735, 2021 | 45 | 2021 |
| Addition of probenecid to oral β-lactam antibiotics: a systematic review and meta-analysis RC Wilson, P Arkell, A Riezk, M Gilchrist, G Wheeler, W Hope, AH Holmes, ... Journal of Antimicrobial Chemotherapy 77 (9), 2364-2372, 2022 | 28 | 2022 |
| A review of available software for adaptive clinical trial design MJ Grayling, GM Wheeler Clinical Trials 17 (3), 323-331, 2020 | 27 | 2020 |
| Early phase clinical trials extension to guidelines for the content of statistical analysis plans V Homer, C Yap, S Bond, J Holmes, D Stocken, K Walker, EJ Robinson, ... bmj 376, 2022 | 26 | 2022 |
| Effectiveness and cost-effectiveness of referral to a commercial open group behavioural weight management programme in adults with overweight and obesity: 5-year follow-up of … AL Ahern, P Breeze, F Fusco, SJ Sharp, N Islam, GM Wheeler, AJ Hill, ... The Lancet Public Health 7 (10), e866-e875, 2022 | 22 | 2022 |
| Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials GM Wheeler, MJ Sweeting, AP Mander Statistics in Medicine 36 (16), 2499-2513, 2017 | 21 | 2017 |
| AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials G Wheeler, M Sweeting, A Mander PLoS ONE 11 (7), e0159026, 2016 | 17 | 2016 |
| Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial DA Fennell, S Danson, PJ Woll, M Forster, D Talbot, J Child, L Farrelly, ... Clinical Cancer Research 26 (18), 4748-4755, 2020 | 15 | 2020 |
| Visualising harms in publications of randomised controlled trials: consensus and recommendations R Phillips, S Cro, G Wheeler, S Bond, TP Morris, S Creanor, C Hewitt, ... bmj 377, 2022 | 11 | 2022 |
| Incoherent dose-escalation in phase I trials using the escalation with overdose control approach G Wheeler Statistical Papers, 1-11, 2016 | 11 | 2016 |
| Designing and evaluating dose-escalation studies made easy: the MoDEsT web app P Pallmann, F Wan, AP Mander, GM Wheeler, C Yap, S Clive, ... Clinical Trials 17 (2), 147-156, 2020 | 9 | 2020 |
| TACTICAL: A phase I/II trial to assess the safety and efficacy of MSCTRAIL in the treatment of metastatic lung adenocarcinoma. A Davies, B Sage, K Kolluri, D Alrifai, R Graham, B Weil, R Rego, O Bain, ... Journal of Clinical Oncology 37 (15_suppl), TPS9116-TPS9116, 2019 | 8 | 2019 |
| Modelling semi‐attributable toxicity in dual‐agent phase I trials with non‐concurrent drug administration GM Wheeler, MJ Sweeting, AP Mander, SM Lee, YKK Cheung Statistics in medicine 36 (2), 225-241, 2017 | 8 | 2017 |
| ALLCAR19: updated data using AUTO1, a novel fast-off rate CD19 CAR in relapsed/refractory B-cell acute lymphoblastic Leukaemia and other B-cell malignancies C Roddie, MA O'Reilly, MAV Marzolini, L Wood, J Dias, AC Garai, ... Blood 136, 3-4, 2020 | 7 | 2020 |
